Sign in
VP

VERTEX PHARMACEUTICALS INC / MA (VRTX)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 was a clean beat: total revenue $3.08B (+11% YoY) and non-GAAP EPS $4.80 versus S&P Global consensus of $3.06B and $4.58, respectively; GAAP EPS $4.20 . EPS and revenue beats vs consensus reflect continued CF strength and early contributions from CASGEVY and JOURNAVX (CASGEVY $16.9M; JOURNAVX $19.6M) .*
  • Full-year guidance refined: revenue raised to $11.9–$12.0B (from $11.85–$12.0B), non-GAAP OpEx increased to $5.0–$5.1B, and non-GAAP ETR cut to 17–18% on one-time tax benefits—net positive for FY EPS .
  • Commercial momentum continues: ALYFTREK transitions drive CF, JOURNAVX surpassed 300k prescriptions and 170M covered lives; CASGEVY global uptake building with 165 first cell collections and 39 infusions cumulatively by Sept 30 .
  • Pipeline catalysts: PoV (povetacicept) BLA rolling review granted, full Phase 3 IgAN enrollment completed; PoV initiated Phase 2/3 in pMN; T1D zimislecel dosing temporarily paused pending internal manufacturing analysis .
  • Stock-reaction catalysts: estimate beat, FY tax-rate reduction, elevated PoV visibility (ASN data, BLA start), and accelerating JOURNAVX adoption—against higher OpEx for launches .

What Went Well and What Went Wrong

What Went Well

  • Strong top-line and EPS beat: “Vertex delivered strong performance across the board in Q3 with $3,080,000,000 in revenue” and diversified growth from CASGEVY and JOURNAVX .
  • Guidance upgrades and tax-rate cut: FY revenue raised; non-GAAP effective tax rate lowered to 17–18% on one-time benefits (Alpine-related R&D credits and deferred tax benefits) .
  • CF franchise momentum: ALYFTREK adoption progressing in the U.S. and early EU markets; management expects majority of TRIKAFTA patients to transition over time due to once-daily dosing and improved CFTR function .

What Went Wrong

  • Elevated operating expenses: non-GAAP combined R&D+AIPR&D+SG&A rose to $1.28B in Q3 (+19% YoY), driven by pipeline acceleration (PoV) and JOURNAVX launch investment; FY non-GAAP OpEx guidance raised to $5.0–$5.1B .
  • JOURNAVX gross-to-net still high: PSP activity remains significant while payer contracting finalizes; management declined to guide 2026 gross-to-net yet .
  • T1D program delay: zimislecel Phase 1/2/3 dosing temporarily postponed pending internal manufacturing analysis, creating near-term uncertainty on timelines .

Financial Results

Revenue and EPS vs Prior Periods and Estimates

MetricQ1 2025Q2 2025Q3 2025
Total Revenue ($USD Billions)$2.770 $2.965 $3.076
GAAP Diluted EPS ($)$2.49 $3.99 $4.20
Non-GAAP Diluted EPS ($)$4.06 $4.52 $4.80
Q3 2025 Actual vs S&P Global ConsensusQ3 2025
Revenue ($USD Billions)$3.076 vs $3.059 (beat)*
EPS (Non-GAAP, $)$4.80 vs $4.58 (beat)*
EPS Estimates (#)22*
Revenue Estimates (#)26*

Values with asterisk retrieved from S&P Global.

Margins

Margin (%)Q1 2025Q2 2025Q3 2025
EBIT Margin %37.2%*38.9%*40.3%*
Net Income Margin %23.3%*34.8%*35.2%*

Values with asterisk retrieved from S&P Global.

Segment/Product Revenue Breakdown

Product Revenues ($USD Millions)Q1 2025Q2 2025Q3 2025
TRIKAFTA/KAFTRIO$2,535.5 $2,551.1 $2,653.6
ALYFTREK$53.9 $156.8 $247.0
Other Product Revenues$170.8 $236.1 $175.8
CASGEVY (in Other)$14.2 $30.4 $16.9
JOURNAVX (in Other)Insignificant $12.0 $19.6
Total Product Revenues$2,760.2 $2,944.0 $3,076.4
Total Revenues$2,770.2 $2,964.7 $3,076.4

Commercial KPIs

KPIQ1 2025Q2 2025Q3 2025
JOURNAVX prescriptions (cumulative in period)>20,000 through Apr 18 >110,000 through mid-Jul >300,000 through mid-Oct
JOURNAVX covered lives (cumulative)~94M total; ~42M unrestricted (as of May 1) ~150M total; 16 Medicaid states unrestricted (mid-Jul) >170M total; 19 Medicaid states unrestricted (mid-Oct)
CASGEVY first cell collections (cumulative)~90 (through May 1) ~115 (through Jun 30) ~165 (through Sep 30; 50 in Q3)
CASGEVY infusions (cumulative)—29 (16 in Q2) 39 (10 in Q3)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total Revenue ($USD Billions)FY 2025$11.85–$12.0B $11.9–$12.0B Raised low end
Combined GAAP R&D, AIPR&D & SG&A ($USD Billions)FY 2025$5.55–$5.7B $5.65–$5.8B Raised
Combined non-GAAP R&D, AIPR&D & SG&A ($USD Billions)FY 2025$4.9–$5.0B $5.0–$5.1B Raised
Non-GAAP Effective Tax RateFY 202520.5%–21.5% 17%–18% Lowered
AIPR&D included (approx.)FY 2025~$100M ~$100M Maintained
Tariff impactFY 2025Immaterial Immaterial Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2)Current Period (Q3)Trend
CF/ALYFTREK uptakeApprovals and anticipated EU access; U.S. launch progressing Majority of TRIKAFTA patients expected to transition over time; strong U.S./EU uptake Accelerating transitions
JOURNAVX access & adoptionEarly scripts (>20k), ~94M covered lives; Phase 4 studies initiated >300k prescriptions, >170M covered lives; 90 systems/750 hospitals on formulary Broadening payer and hospital access
CASGEVY roll-out>65 ATCs; ~90 collections ~165 collections; reimbursement in Italy; >100M FY revenue expected Building momentum across regions
PoV (povetacicept)IgAN interim cohort enrolled; pMN pivotal plan set BLA rolling review; first module by YE; full Phase 3 IgAN enrollment; pMN Phase 2/3 initiated De-risking regulatory path
Tax rate and OpExNon-GAAP ETR 20.5–21.5%; OpEx investments ongoing ETR cut to 17–18% on one-time benefits; OpEx up for PoV & JOURNAVX EPS tailwind; spend rising
T1D (zimislecel)Phase 3 dosing near-term; 2026 filings expected Dosing temporarily postponed pending internal manufacturing analysis Near-term delay

Management Commentary

  • “Vertex delivered strong performance across the board in Q3 with $3,080,000,000 in revenue ... growing global momentum of CASGEVY and broad uptake of JOURNAVX … preparing for new launches in additional disease areas.” — Reshma Kewalramani, CEO .
  • “We now expect 2025 total revenue to be in a range of 11.9 … to $12,000,000,000 … over $100,000,000 of CASGEVY revenue … further contribution from JOURNAVX due to growing prescription volumes.” — Charlie Wagner, CFO .
  • “Outside the U.S., early launch of ALYFTREK is off to a strong start … majority of patients around the globe will transition to ALYFTREK over time given its multiple benefits.” — Duncan McKechnie, CCO .
  • “PoV offers … every four weeks, at-home administration via a subcutaneous auto injector and the lowest dosage volume … we believe PoV holds best-in-class potential.” — Duncan McKechnie .
  • “We have completed full enrollment in the RAINIER Phase 3 trial [IgAN] … will begin our submission for potential accelerated approval before the end of this year.” — Reshma Kewalramani .

Q&A Highlights

  • ALYFTREK transitions: Vast majority of newly eligible U.S. patients started; steady transitions from TRIKAFTA; ~$0.5B revenue since launch over ~10 months .
  • PoV differentiation: Dual BAFF/APRIL inhibition matches disease biology; engineered for tissue penetration; PD markers (proteinuria, hematuria, Gd-IgA1) expected to correlate with eGFR stabilization; BLA rolling review granted after pre-BLA meeting .
  • JOURNAVX access: >170M covered lives; productive talks with the third PBM; PSP extended into 2026 to ensure access; scripts ramped (10k Q1, 90k Q2, 170k Q3, plus October) .
  • Gross-to-net: Elevated due to active PSP; management not ready to guide 2026 gross-to-net until payer mix settles .
  • No Pain Act: Final list delayed due to government shutdown; company advocating inclusion; multiple Phase 4 datasets forthcoming (opioid reduction focus now; time-to-discharge analyses in future) .

Estimates Context

  • Q3 2025 delivered a revenue and EPS beat versus S&P Global consensus: $3.076B actual vs $3.059B estimate and $4.80 non-GAAP EPS actual vs $4.58 estimate; 26 revenue and 22 EPS estimates contributed to the consensus.* This, alongside the non-GAAP tax-rate reduction, should prompt upward revisions to FY EPS trajectories.*

Values with asterisk retrieved from S&P Global.

Key Takeaways for Investors

  • Clean beat-and-raise quarter: top-line and non-GAAP EPS ahead of consensus, with FY non-GAAP ETR cut to 17–18% creating a near-term EPS tailwind .*
  • CF durability with ALYFTREK transitions supports multi-year growth; management expects majority of TRIKAFTA patients to move to ALYFTREK over time .
  • JOURNAVX is scaling: prescriptions and payer coverage expanding; OpEx investment (field force expansion in 2026) aims to accelerate adoption—watch gross-to-net normalization trajectory .
  • CASGEVY execution improving with more ATCs, collections, infusions; >$100M FY25 revenue targeted—monitor reimbursement and throughput metrics into 2026 .
  • PoV de-risking: BLA rolling review and full Phase 3 IgAN enrollment completed; ASN data and BLA initiation are near-term catalysts; best-in-class positioning via dual BAFF/APRIL inhibition .
  • Expense discipline vs growth: higher non-GAAP OpEx to support launches and pivotal programs; weigh margin trajectory (EBIT margin improving Q1→Q3) against investment needs .*
  • Tactical setup: Near-term catalysts include PoV ASN updates/BLA start, continued JOURNAVX contracting (third PBM), CASGEVY ramp, and potential T1D manufacturing resolution; risk includes elevated PSP/gross-to-net and T1D dosing pause .

Any other relevant press releases for Q3 2025: No additional Vertex-specific press releases beyond the 8-K earnings release were identified in the period. The notable operational updates are captured within the 8-K and the earnings call – –.

Values with asterisk retrieved from S&P Global.